Skip to main content

Advertisement

Table 1 Completed immunotherapy clinical trials in ES-SCLC

From: Emerging therapies for small cell lung cancer

Phase Study Treatment arms Patients (n) ORR (%) PFS (months) OS (months)
First line
 II NCT01331525 Ipilimumab + carboplatin + cisplatin; maintained with ipilimumab 42 72.4 6.9 17.0
 II CA184-041 Ipilimumab/placebo + carboplatin + paclitaxel vs. placebo/ipilimumab + carboplatin + paclitaxel vs. placebo + carboplatin + paclitaxel; maintained with ipilimumab vs. placebo 128 32 vs. 57 vs. 49 5.7 vs. 6.4 vs. 5.3* (HR = 0.75, 0.64) (P = 0.11, 0.03) 9.1 vs. 12.9 vs. 9.9 (HR = 0.95, 0.75) (P = 0.41, 0.13)
 III CA184-156 Ipilimumab + etoposide + cisplatin/carboplatin vs. placebo + etoposide + cisplatin/carboplatin; maintained with ipilimumab vs. placebo 954 62 vs. 62 4.6 vs. 4.4 (HR = 0.85) (P = 0.016) 11 vs. 10.9 (HR = 0.94) (P = 0.38)
 III Impower-133 Atezolizumab + carboplatin + etoposide vs. placebo + carboplatin + etoposide; maintained with atezolizumab vs. placebo 403 60.2 vs. 64.4 5.2 vs. 4.3 (HR = 0.77) (P = 0.02) 12.3 vs. 10.3 (HR = 0.70) (P = 0.007)
Maintenance
 II NCT02359019 Pembrolizumab 45 11.1 1.4 9.6
Relapsed
 I/II CheckMate-032 Nivolumab 3 mg/kg vs. nivolumab 1 mg/kg + ipilimumab 3 mg/kg vs. nivolumab 3 mg/kg + ipilimumab 1 mg/kg 213 10 vs. 23 vs. 19 1.4 vs. 2.6 vs. 1.4 4.4 vs. 7.7 vs. 6.0
 IB KEYNOTE-028 Pembrolizumab 24 33.3 1.9 9.7
 II KEYNOTE-158 Pembrolizumab 107 18.7 2.0 9.1
 I/II NCT02261220 Durvalumab + tremelimumab 30 13.3 1.8 7.9
  1. *irPFS